Table 3.
Compound | IC50a (μM) | CC50b (μM) | |||
---|---|---|---|---|---|
NL4-3 | NL4-3/V370A | ||||
19 | 7 | 0.01 ± 0.004 (2) | 2.6 ± 1.2 (2) | >10 | |
20 | 7 | 0.01 ± 0.003 (2) | 0.37 ± 0.15 (2) | 7.9 ± 0.65 (2) | |
21 | 8 | 0.03 ± 0.007 (3) | 0.36 ± 0.13 (3) | >10 | |
22 | 8 | 0.15 ± 0.05 (2) | 0.33 ± 0.04 (2) | >10 | |
23 | 8 | 0.02 ± 0.0072 (2) | 0.92 ± 0.21 (2) | >10 | |
24 | 8 | 0.03 ± 0.014 (2) | 0.33 ± 0.25 (2) | >10 | |
25 | 8 | 0.04 ± 0.018 (2) | 0.95 ± 0.34 (2) | >10 | |
26 | 9 | 0.02 ± 0.008 (2) | 1.20 ± 0.13 (2) | >10 | |
27 | 9 | 0.05 ± 0.016 (2) | 1.58 ± 0.33 (2) | >10 | |
28 | 9 | 0.02 ± 0.007 (2) | 1.04 ± 0.42 (2) | >10 | |
29 | 9 | 0.04 ± 0.019 (2) | 0.34 ± 0.22 (2) | 8.3± 0.56 (2) |
C50: concentration that inhibited HIV-1 replication by 50%; presented as mean +/- SD.
CC50: concentration that reduced cell viability by 50%. IC50 and CC50 were determined by using CalcuSyn (Biosoft). The numbers in the parentheses represent the number of tests.